Ophthalmological Conditions

Ophthalmological Conditions

The retina is one of the most metabolically demanding tissues in the human body: its photoreceptor cells consume oxygen at rates comparable to those of the cerebral cortex.

This extremely high energy demand makes it highly sensitive to any disruption in blood flow; even a few minutes of ischemia can be sufficient to cause irreversible damage.

Hyperbaric oxygen chamber therapy is of particular importance in vascular diseases of the eye precisely because of this characteristic: by providing amounts of oxygen that reach the retina independently of obstructed or dysfunctional blood vessels, it gives photoreceptors and ganglion cells a critical second chance for survival.

Always as an emergency adjunctive intervention, alongside time-critical ophthalmological management.

Key Characteristics of the Treatment

In vascular diseases of the eye, hyperbaric oxygen chamber therapy utilizes a unique physiological mechanism: under hyperbaric conditions, the amount of oxygen dissolved in the plasma increases so dramatically that it can supply the retina independently of the condition of the retinal arteries and veins.

The vitreous humor and the aqueous layers surrounding the retina function as alternative pathways for oxygen diffusion.

At the same time, hyperbaric oxygen induces vasoconstriction in normal blood vessels, a phenomenon that reduces intraocular edema and may paradoxically improve blood flow to adjacent ischemic areas.

In addition, it activates anti-apoptotic mechanisms that delay neuronal death and provide time for restoration of the primary vascular injury.

Scientific Basis

The use of hyperbaric oxygen in vascular diseases of the eye is based on a body of clinical studies, case series, and experimental data documenting the preservation of visual function in acute ischemic conditions.

The UHMS recognizes central retinal artery occlusion as an indication, emphasizing that the therapeutic window is extremely narrow and that effectiveness is directly associated with how quickly treatment is initiated.

In all applications, the therapy is incorporated as an emergency adjunctive intervention; it does not replace ophthalmological evaluation or specialized interventional techniques, but provides biological support to ischemic tissue while these interventions are being performed or awaited.